Literature DB >> 18820714

Diastereoselectivity of the P2Y11 nucleotide receptor: mutational analysis.

D Ecke1, B Fischer, G Reiser.   

Abstract

BACKGROUND AND
PURPOSE: The P2Y(11) receptor, a member of the group of metabotropic nucleotide receptors, shows a stereospecific ligand recognition of P(alpha)-substituted ATP derivatives (ATP-alpha-S isomers). These compounds are suitable candidates for the development of selective P2Y(11) receptor agonists that might be used as immune modulators. We have analysed the binding mode of ATP at the P2Y(11) receptor by molecular modeling and site-directed mutagenesis. Based on our recent findings, we decided to decipher the molecular determinants of stereoselective recognition at the P2Y(11) receptor. EXPERIMENTAL APPROACH: Two amino acid residues [Glu186 in the extracellular loop 2 and Arg268 in the transmembrane domain 6 (TM6)], which are part of the nucleotide-binding pocket, were selected and studied by mutational analyses. We expected these residues to be involved in determining the stereospecificity of the P2Y(11) receptor. KEY
RESULTS: After mutation of Arg268 to alanine or glutamine, the stereospecific recognition of the ATP-alpha-S isomers at the P2Y(11) receptor was lost. In contrast, at the Glu186Ala receptor mutant, the stereoselective differentiation between these isomers was increased. On the Arg268Gln/Glu186Ala double mutant we observed no further effect, except for additivity in the decrease in potency of both isomers, as compared with the single-point mutants. CONCLUSIONS AND IMPLICATIONS: Our results show that the stereospecificity of the P2Y(11) receptor for P(alpha)-substituted ATP derivatives is largely determined by the basic residue Arg268 in TM6. This will allow the design of receptor-subtype selective ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820714      PMCID: PMC2607205          DOI: 10.1038/bjp.2008.352

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  P2Y(11) receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors.

Authors:  A D Conigrave; K C Fernando; B Gu; V Tasevski; W Zhang; B M Luttrell; J S Wiley
Journal:  Eur J Pharmacol       Date:  2001-08-31       Impact factor: 4.432

2.  Adenosine 5'-O-(1-boranotriphosphate) derivatives as novel P2Y(1) receptor agonists.

Authors:  Victoria Nahum; Gregor Zündorf; Sébastien A Lévesque; Adrien R Beaudoin; Georg Reiser; Bilha Fischer
Journal:  J Med Chem       Date:  2002-11-21       Impact factor: 7.446

3.  Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11.

Authors:  Stefan Amisten; Olle Melander; Anna-Karin Wihlborg; Göran Berglund; David Erlinge
Journal:  Eur Heart J       Date:  2006-11-29       Impact factor: 29.983

4.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

5.  Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.

Authors:  Hak Sung Kim; R Gnana Ravi; Victor E Marquez; Savitri Maddileti; Anna-Karin Wihlborg; David Erlinge; Malin Malmsjö; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

6.  Pharmacological characterization of the human P2Y11 receptor.

Authors:  D Communi; B Robaye; J M Boeynaems
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

7.  An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y11 receptors.

Authors:  A D Qi; A C Zambon; P A Insel; R A Nicholas
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

8.  Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes.

Authors:  Iliana Moreschi; Santina Bruzzone; Robert A Nicholas; Floriana Fruscione; Laura Sturla; Federica Benvenuto; Cesare Usai; Sabine Meis; Matthias U Kassack; Elena Zocchi; Antonio De Flora
Journal:  J Biol Chem       Date:  2006-08-22       Impact factor: 5.157

9.  Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues.

Authors:  D Ecke; M E Tulapurkar; V Nahum; B Fischer; G Reiser
Journal:  Br J Pharmacol       Date:  2006-09-04       Impact factor: 8.739

10.  Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis.

Authors:  Jacques Zylberg; Denise Ecke; Bilha Fischer; Georg Reiser
Journal:  Biochem J       Date:  2007-07-15       Impact factor: 3.857

View more
  5 in total

Review 1.  G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Authors:  Kenneth A Jacobson; Ramachandran Balasubramanian; Francesca Deflorian; Zhan-Guo Gao
Journal:  Purinergic Signal       Date:  2012-02-29       Impact factor: 3.765

Review 2.  A critical look at the function of the P2Y11 receptor.

Authors:  Karin Dreisig; Birgitte Rahbek Kornum
Journal:  Purinergic Signal       Date:  2016-05-31       Impact factor: 3.765

3.  Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes.

Authors:  Kenneth A Jacobson; M P Suresh Jayasekara; Stefano Costanzi
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-09-12

Review 4.  Adenosine-associated delivery systems.

Authors:  Mehdi Kazemzadeh-Narbat; Nasim Annabi; Ali Tamayol; Rahmi Oklu; Amyl Ghanem; Ali Khademhosseini
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

5.  Emerging role of extracellular nucleotides and adenosine in multiple sclerosis.

Authors:  Marek Cieślak; Filip Kukulski; Michał Komoszyński
Journal:  Purinergic Signal       Date:  2011-07-27       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.